A Phase 1 interventional study of Experimental: aprepitant and Experimental: fosaprepitant in Chemotherapy-Induced Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2018-09-25.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.
Among the 61 studies testing aprepitant in Vomiting, this one is the 31st largest by enrollment, is one of 6 that started in 2009, is one of 6 in phase 1, and was the 17th registered.
794 studies on the registry are indexed under Vomiting; 99 are open to participants now.
Browse Vomiting studies →3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–75
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is below the median of 103 across 673 interventional studies indexed under Vomiting.
Median enrollment 92 across the 61 interventional studies. Of the 45 that completed or were terminated, 25 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 61 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
29 studies in Vomiting by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 29 finished, 20 (69%) have results posted.
Among the 29 studies in Vomiting by Merck & Co., Inc, this one is the 21st largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2009, is one of 6 in phase 1, and was the 14th registered.
Merck & Co., Inc’s Vomiting studies by the year they started, since 2002.
1 of the studies testing aprepitant in Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07371728Sir Mortimer B. Davis - Jewish General HospitalEffect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 61 studies testing aprepitant in Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 29 in Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after intravenous administration; the pharmacological effect of fosaprepitant is attributed to aprepitant. The birth to one year old cohort will be initiated in Parts III and IV upon completion of Part II (Steps A and B) in participants \<6 months of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Drug: Experimental: aprepitant · Drug: Experimental: fosaprepitant · Drug: Ondansetron · Drug: Dexamethasone
Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Drug: Experimental: fosaprepitant · Drug: Ondansetron · Drug: Dexamethasone
Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to \<12 years of age - 47 mg/m\^2; 4 months to \<6 months of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Drug: Experimental: aprepitant · Drug: Ondansetron · Drug: Dexamethasone
Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to \<12 years of age - 74 mg/m\^2; 6 months to \<2 years of age - 1.3 mg/kg; 4 months to \<6 months of age - 3.0 mg/kg; 1 month to \<4 months of age - 1.5 mg/kg; birth to \<1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Drug: Experimental: aprepitant · Drug: Ondansetron · Drug: Dexamethasone
Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to \<12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
Drug: Comparator: ondansetron · Drug: Dexamethasone
Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to \<12 years of age - 3.0 mg/kg; 1 month to \<4 months of age - 1.5 mg/kg; Birth to \<1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to \<12 years of age - 2.0 mg/kg; 1 month to \<4 months of age - 1.0 mg/kg; Birth to \<1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
Drug: Experimental: aprepitant · Drug: Ondansetron · Drug: Dexamethasone
Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to \<12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
Drug: Experimental: fosaprepitant · Drug: Ondansetron · Drug: Dexamethasone
aprepitant powder for suspension, 125 mg/sachet, PO
Also known as: Emend, MK-0869
fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
Also known as: Emend injection, Fosaprepitant Dimeglumine, MK-0517
ondansetron solution for infusion, IV, administered per local standard of care
Also known as: Zofran
ondansetron solution for infusion, IV, administered per local standard of care
dexamethasone solution for infusion, IV, administered per local standard of care
Area Under the Time-Concentration Curve From 0 to 24 Hours (AUC 0-24hr) for Aprepitant
AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.
Time frame: Up to 24 hours post fosaprepitant/aprepitant dose
Maximum Plasma Concentration (Cmax) for Aprepitant
Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
Time frame: Up to 72 hours post fosaprepitant/aprepitant dose
Time to Cmax (Tmax) for Aprepitant
Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
Time frame: Up to 72 hours post fosaprepitant/aprepitant dose
Apparent Terminal Half-life (t1/2) for Aprepitant
t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
Time frame: Up to 72 hours post fosaprepitant/aprepitant dose
Cmax for Fosaprepitant
Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
Time frame: Up to 72 hours post fosaprepitant dose
Tmax for Fosaprepitant
Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
Time frame: Up to 72 hours post fosaprepitant dose
Number of Participants Experiencing Adverse Events (AEs)
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.
Time frame: Up to 14 days after last dose of study drug (Up to 17 days)
Number of Participants Discontinuing Study Drug Due to an AE
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.
Time frame: Day 1 up to Day 3
Plasma Concentration and PK Parameters of Dexamethasone in Participants From Birth to 1 Year of Age
Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.
Time frame: Up to 24 hours post dexamethasone dose
| Milestone | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part IV-Additional Enrollers | Part V-fosaprepitant Regimen | Part V-Additional Enrollers |
|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 11 | 19 | 20 | 19 | 0 | 5 | 0 | 6 |
| Completed | 12 | 11 | 19 | 20 | 19 | 0 | 5 | 0 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part IV-Additional Enrollers | Part V-fosaprepitant Regimen | Part V-Additional Enrollers |
|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 11 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part IV-Additional Enrollers | Part V-fosaprepitant Regimen | Part V-Additional Enrollers |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 19 | 20 | 0 | 0 | 0 | 0 | 0 |
| Treated | 0 | 0 | 19 | 19 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 18 | 18 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Not treated | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part IV-Additional Enrollers | Part V-fosaprepitant Regimen | Part V-Additional Enrollers |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part IV-Additional Enrollers | Part V-fosaprepitant Regimen | Part V-Additional Enrollers |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 15 | 5 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 14 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part IV-Additional Enrollers | Part V-fosaprepitant Regimen | Part V-Additional Enrollers |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
AUC is a measure of the amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for pharmacokinetic (PK) assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hours (hr) post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy.
| hr*ng/mL | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| 6 months to <2 years (n=0, 0, 5, 5, 0, 6, 6) | NA ± NA | NA ± NA | 20000 ± 7890 | 6310 ± 2040 | — | 21100 ± 11800 | 11700 ± 6980 |
| 2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7) | NA ± NA | NA ± NA | 16400 ± 8080 | 23000 ± 8390 | — | 17300 ± 5060 | 18300 ± 11100 |
| 6 years to <12 years (n=0, 0, 6, 6, 0, 6, 8) | NA ± NA | NA ± NA | 16000 ± 4810 | 22000 ± 9440 | — | 24400 ± 15800 | 19500 ± 6720 |
| 12 years to 17 years (n=8, 11, 0, 0, 0, 0, 0) | 19500 ± 8010 | 30800 ± 7020 | NA ± NA | NA ± NA | — | NA ± NA | NA ± NA |
Cmax is a measure of the maximum amount of aprepitant in the plasma. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
| ng/mL | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| 6 months to <2 years (n=0, 0, 5, 5, 0, 6, 7) | NA ± NA | NA ± NA | 1930 ± 1000 | 659 ± 107 | — | 1810 ± 925 | 1700 ± 636 |
| 2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7) | NA ± NA | NA ± NA | 1300 ± 609 | 2100 ± 1170 | — | 1840 ± 933 | 2430 ± 1100 |
| 6 years to <12 years (n=0, 0, 6, 6, 0, 7, 8) | NA ± NA | NA ± NA | 1300 ± 275 | 1930 ± 873 | — | 1800 ± 1610 | 2850 ± 641 |
| 12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0) | 3240 ± 1280 | 5870 ± 2770 | NA ± NA | NA ± NA | — | NA ± NA | NA ± NA |
Tmax is a measure of the amount of time after dosing to when the maximum concentration of aprepitant was achieved. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
| hr | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| 6 months to <2 years (n=0, 0, 5, 5, 0, 6, 7) | NA ± NA | NA ± NA | 2.33 ± 1.16 | 3.45 ± 2.89 | — | 7.34 ± 8.28 | 1.13 ± 0.17 |
| 2 years to <6 years (n=0, 0, 8, 7, 0, 6, 7) | NA ± NA | NA ± NA | 3.78 ± 1.92 | 5.28 ± 1.97 | — | 4.92 ± 2.20 | 1.41 ± 0.83 |
| 6 years to <12 years (n=0, 0, 6, 6, 0, 7, 8) | NA ± NA | NA ± NA | 5.17 ± 1.83 | 3.08 ± 0.95 | — | 6.42 ± 7.84 | 1.07 ± 0.11 |
| 12 years to 17 years (n=12, 11, 0, 0, 0, 0, 0) | 0.41 ± 0.27 | 0.64 ± 0.30 | NA ± NA | NA ± NA | — | NA ± NA | NA ± NA |
t1/2 is the amount of time from dosing until half of the aprepitant was metabolized from the body. Fosaprepitant is a prodrug for aprepitant and is rapidly converted to aprepitant after IV administration. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part IB - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy; Parts II and IV - Pre-dose and 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post aprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
| hr | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| 6 months to <2 years (n=0, 0, 5, 3, 0, 3, 6) | NA ± NA | NA ± NA | 7.28 ± 1.47 | 8.09 ± 2.54 | — | 6.18 ± 4.12 | 7.71 ± 3.10 |
| 2 years to <6 years (n=0, 0, 6, 4, 0, 5, 7) | NA ± NA | NA ± NA | 8.27 ± 2.67 | 6.06 ± 3.03 | — | 9.21 ± 5.57 | 6.44 ± 2.35 |
| 6 years to <12 years (n=0, 0, 5, 6, 0, 4, 8) | NA ± NA | NA ± NA | 9.17 ± 4.00 | 6.89 ± 1.35 | — | 10.8 ± 4.27 | 8.76 ± 3.34 |
| 12 years to 17 years (n=6 11, 0, 0, 0, 0, 0) | 11.0 ± 4.42 | 22.2 ± 19.8 | NA ± NA | NA ± NA | — | NA ± NA | NA ± NA |
Cmax is a measure of the maximum amount of fosaprepitant in the plasma. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
| ng/mL | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| 6 months to <2 years (n=0, 0, 0, 0, 0, 0, 7) | — | NA ± NA | — | — | — | — | 2756 ± 3364 |
| 2 years to <6 years (n=0, 0, 0, 0, 0, 0, 8) | — | NA ± NA | — | — | — | — | 3034 ± 1718 |
| 6 years to <12 years (n=0, 0, 0, 0, 0, 0, 8) | — | NA ± NA | — | — | — | — | 1654 ± 1995 |
| 12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0) | — | 1310 ± 964 | — | — | — | — | NA ± NA |
Tmax is a measure of the amount of time after dosing to when the maximum concentration of fosaprepitant was achieved. Blood samples for PK assessment were collected at the following time points: Part IA - Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 24 hr post fosaprepitant dose; Part V - Pre-dose and -0.75, -0.5, 0, 0.5, 1.5, 3, 4, 6, 8, 24, 48 and 72 hr post start of chemotherapy.
| hr | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| 6 months to <2 years (n=0, 0, 0, 0, 0, 0, 7) | — | NA ± NA | — | — | — | — | 1.13 ± 0.175 |
| 2 years to <6 years (n=0, 0, 0, 0, 0, 0, 7) | — | NA ± NA | — | — | — | — | 1.05 ± 0.089 |
| 6 years to <12 years (n=0, 0, 0, 0, 0, 0, 8) | — | NA ± NA | — | — | — | — | 1.04 ± 0.088 |
| 12 years to 17 years (n=0, 11, 0, 0, 0, 0, 0) | — | 0.614 ± 0.251 | — | — | — | — | NA ± NA |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for the occurrence AEs for up to 14 days after last dose of study drug.
| Participants | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 11 | 6 | 18 | 16 | 15 | 13 | 17 |
Blood samples for PK assessment were to be collected at the following time points: Parts II and V - Pre-dose and 1.5, 3, 4, 6, 8 and 24 hr post start of chemotherapy; Parts III and IV - Immediately after infusion of dexamethsone and 0.5, 1.5, 3, 8 and 24 hr post start of chemotherapy.
No measurements were reported for this outcome.
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. The number of participants who discontinued from the study due to an AE are summarized.
| Participants | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| Number of Participants Discontinuing Study Drug Due to an AE | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over Up to 14 days after last dose of study drug (Up to 17 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part IA-fosaprepitant 115 mg/Aprepitant | — | 4/12 (33.3%) | 11/12 (91.7%) |
| Part IB-fosaprepitant 150 mg | — | 1/11 (9.1%) | 5/11 (45.5%) |
| Part IIA-aprepitant 80 mg Equiv. | — | 7/19 (36.8%) | 18/19 (94.7%) |
| Part IIB-aprepitant 125 mg Equiv. | — | 4/19 (21.1%) | 15/19 (78.9%) |
| Part III-ondansetron | — | 5/19 (26.3%) | 15/19 (78.9%) |
| Part IV-aprepitant Regimen | — | 2/20 (10%) | 13/20 (65%) |
| Part V-fosaprepitant Regimen | — | 9/23 (39.1%) | 16/23 (69.6%) |
| Event | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/12 | 0/11 | 4/19 | 2/19 | 4/19 | 2/20 | 4/23 |
| NeutropeniaBlood and lymphatic system disorders | 1/12 | 0/11 | 2/19 | 1/19 | 0/19 | 0/20 | 2/23 |
| VomitingGastrointestinal disorders | 0/12 | 0/11 | 2/19 | 0/19 | 0/19 | 0/20 | 0/23 |
| Enterobacter bacteraemiaInfections and infestations | 0/12 | 1/11 | 0/19 | 0/19 | 0/19 | 0/20 | 0/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/12 | 0/11 | 0/19 | 1/19 | 0/19 | 0/20 | 0/23 |
| Septic shockInfections and infestations | 1/12 | 0/11 | 0/19 | 0/19 | 0/19 | 0/20 | 0/23 |
| LymphopeniaBlood and lymphatic system disorders | 0/12 | 0/11 | 0/19 | 1/19 | 0/19 | 0/20 | 0/23 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/11 | 1/19 | 0/19 | 0/19 | 0/20 | 0/23 |
| EnteritisGastrointestinal disorders | 0/12 | 0/11 | 0/19 | 0/19 | 1/19 | 0/20 | 0/23 |
| NauseaGastrointestinal disorders | 0/12 | 0/11 | 1/19 | 0/19 | 0/19 | 0/20 | 0/23 |
| Event | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen |
|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 5/12 | 0/11 | 9/19 | 8/19 | 2/19 | 1/20 | 5/23 |
| NauseaGastrointestinal disorders | 3/12 | 0/11 | 2/19 | 6/19 | 0/19 | 1/20 | 1/23 |
| PyrexiaGeneral disorders | 0/12 | 0/11 | 2/19 | 1/19 | 1/19 | 1/20 | 7/23 |
| AnaemiaBlood and lymphatic system disorders | 3/12 | 0/11 | 0/19 | 5/19 | 5/19 | 3/20 | 3/23 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/12 | 0/11 | 0/19 | 3/19 | 4/19 | 5/20 | 4/23 |
| DizzinessNervous system disorders | 3/12 | 0/11 | 0/19 | 0/19 | 0/19 | 1/20 | 1/23 |
| NeutropeniaBlood and lymphatic system disorders | 1/12 | 0/11 | 2/19 | 4/19 | 3/19 | 3/20 | 5/23 |
| Abdominal painGastrointestinal disorders | 1/12 | 0/11 | 2/19 | 4/19 | 1/19 | 1/20 | 3/23 |
| ConstipationGastrointestinal disorders | 0/12 | 1/11 | 0/19 | 0/19 | 3/19 | 1/20 | 1/23 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 1/11 | 1/19 | 1/19 | 3/19 | 1/20 | 2/23 |
For analysis purposes, baseline (BL) data are presented by study part groups. The BL analysis population includes all unique enrolled participants in Parts I, II, III, IV and V. Part III participants who entered Parts IV and V are only counted in Part III; Part IV participants who entered Part V are only counted in Part IV.
| Age, Customized(Participants) | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen | Total |
|---|---|---|---|---|---|---|---|---|
| 6 months to <2 years | 0 | 0 | 5 | 6 | 6 | 1 | 1 | 19 |
| 2 years to <6 years | 0 | 0 | 8 | 8 | 6 | 0 | 3 | 25 |
| 6 years to <12 years | 0 | 0 | 6 | 6 | 7 | 4 | 2 | 25 |
| 12 years to 17 years | 12 | 11 | 0 | 0 | 0 | 0 | 0 | 23 |
| Sex: Female, Male(Participants) | Part IA-fosaprepitant 115 mg/Aprepitant | Part IB-fosaprepitant 150 mg | Part IIA-aprepitant 80 mg Equiv. | Part IIB-aprepitant 125 mg Equiv. | Part III-ondansetron | Part IV-aprepitant Regimen | Part V-fosaprepitant Regimen | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 7 | 12 | 14 | 13 | 3 | 6 | 62 |
| Male | 5 | 4 | 7 | 6 | 6 | 2 | 0 | 30 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Feb 2009 to primary completion in Jan 2014, 59 months.
Results were first posted in Nov 2014, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aprepitant · Fosaprepitant · Ondansetron